Drug intelligence / Profile preview

ZCL279

Development stage: Unknown
Modality: Small Molecules

Overview

ZCL279 is a small molecule modulator that targets Cdc42, a cytoplasmic small GTPase belonging to the Ras superfamily. Its mechanism involves inhibiting the interaction between Cdc42 and intersectin (ITSN). Notably, ZCL279 exhibits a concentration-dependent dual effect on Cdc42: it acts as an activator at lower concentrations (less than 10 μM) and as a significant inhibitor at higher concentrations (greater than 10 μM). It is currently available as a research reagent.

Targets

CDC42 (Cell division control protein 42 homolog)

Beyond the preview

Go deeper on ZCL279.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZCL279.

Explore the full profile